Loading...
Market
Will Novavax's share price increase by more than 10% by Nov 30, 2024, following EU authorization?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from Nasdaq or financial news outlets
Story
Novavax's Shares Rise as EU Authorizes Updated Nuvaxovid COVID-19 Vaccine Targeting JN.1 Strain
Oct 9, 2024, 12:30 PM
Novavax Inc.'s updated 2024-2025 Nuvaxovid COVID-19 vaccine has received authorization from the European Commission, the company announced on Wednesday. The vaccine, which targets the JN.1 strain of the coronavirus, is approved for preventing COVID-19 in individuals aged 12 years and older across the European Union. Following the news, Novavax's shares rose 3.2% in premarket trading.
View original story
Similar markets
Increase by more than 20% • 25%
Increase by 0-20% • 25%
Decrease by 0-20% • 25%
Decrease by more than 20% • 25%
